Related Experiment Video
Updated: May 6, 2026
Imaging Glioma Initiation In Vivo Through a Polished and Reinforced Thin-skull Cranial Window
Published on: November 20, 2012
Experiment research on inhibition of glioma with sTRAIL in vitro
Yihe Dou1, Yangang Wang, Jian Xu
1Department of Neurosurgery, The Affiliated Hospital of Medical College, Qingdao University , Shandong Province , P. R. China.
Abstract:
We report that adenovirus mediated TNF-related apoptosis-inducing ligand (TRAIL) influenced the cell growth and cell cycle in the glioma cells in vitro. After being infected with the Ad-sTRAIL, U251 cell growth was inhibited. The expression of sTRAIL was detected using immunofluorescence. The higher rate of apoptosis was demonstrated using short-term microculture tetrazoliun (MTT) assay and flow cytometry. The rate of Ad-sTRAIL-inducing U251 cell apoptosis was increased depending on the dosage and the time. The apoptosis of G0/G1 and S phase cells was more significant than that of the control groups. The growth and proliferation of U251 cell line was inhibited after the infection of Ad-sTRAIL. It is dose- and time dependent.
Insights
Adenovirus-mediated TNF-related apoptosis-inducing ligand (TRAIL) effectively inhibited glioma cell growth and proliferation. This study demonstrates Ad-sTRAIL
Area of Science:
- Oncology
- Molecular Biology
- Virology
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with limited treatment options.
- Targeting apoptosis pathways is a promising strategy for cancer therapy.
- Adenovirus-mediated gene delivery offers a potential method for delivering therapeutic agents like TRAIL.
Purpose of the Study:
- To investigate the efficacy of adenovirus-mediated TNF-related apoptosis-inducing ligand (Ad-sTRAIL) in inhibiting glioma cell growth and inducing apoptosis in vitro.
- To determine the dose- and time-dependent effects of Ad-sTRAIL on U251 glioma cells.
- To analyze the impact of Ad-sTRAIL on the cell cycle progression of glioma cells.
Main Methods:
- U251 glioma cells were infected with Ad-sTRAIL.
- sTRAIL expression was confirmed using immunofluorescence.
- Cell viability and apoptosis rates were assessed using MTT assay and flow cytometry.
- Cell cycle distribution was analyzed by flow cytometry.
Main Results:
- Ad-sTRAIL infection significantly inhibited U251 glioma cell growth and proliferation.
- A dose- and time-dependent increase in apoptosis was observed following Ad-sTRAIL treatment.
- Apoptosis was significantly induced in G0/G1 and S phases of the cell cycle.
- sTRAIL expression was successfully detected in infected cells.
Conclusions:
- Adenovirus-mediated delivery of TRAIL is a potent inducer of apoptosis in glioma cells.
- Ad-sTRAIL demonstrates a dose- and time-dependent inhibitory effect on glioma cell growth.
- Targeting apoptosis pathways with Ad-sTRAIL presents a potential therapeutic strategy for glioblastoma.
